Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo Nordisk defended its obesity drug CagriSema despite disappointing trial data. The company remains optimistic about its efficacy compared to Wegovy. Upcoming trials aim to harness its weight-loss ...

CagriSema could still be a commercial success, though, and amycretin's recent results highlight the fact that Novo Nordisk's weight loss pipeline is deep. And regarding the slower-than-expected ...

Wegovy and Other New Weight Loss Drugs Actually Work—so What ... actually dropped when it announced that their drug candidate CagriSema (a mix of semaglutide with the experimental drug ...

Investors had dumped Novo shares in late December when data on a highly touted experimental Novo weight-loss shot called CagriSema fell far short of the expectations the company had set.

The Street broadly expected the Redefine-1 trial of CagriSema to show ~25% weight loss, raising the benchmark injectables in development. Viking Therapeutics highlighted new clinical data from its ...

The amycretin data looks stronger than the 19% weight loss at 36 weeks generated for Lilly’s next-generation drug retatrutide in phase 2 (phase 3 data is expected in 2026) and 20.4% cagrisema ...

CagriSema could still be a commercial success, though, and amycretin's recent results highlight the fact that Novo Nordisk's weight loss pipeline is deep.